Intelligent Bio Solutions Inc.
INBS · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.95 | 0.47 |
| FCF Yield | -109.24% | -168.02% | -11.76% | -3.21% |
| EV / EBITDA | -0.88 | -0.07 | -7.12 | -13.01 |
| Quality | ||||
| ROIC | -334.68% | -109.48% | -238.95% | -108.42% |
| Gross Margin | 40.85% | 45.81% | 25.99% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.94 | 0.69 | 0.40 |
| Growth | ||||
| Revenue 3-Year CAGR | 34.42% | – | -14.06% | -100.00% |
| Free Cash Flow Growth | -1.19% | -24.24% | -110.86% | 66.91% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | 0.55 | -0.04 | 0.99 |
| Interest Coverage | -174.82 | -61.52 | -56.35 | -1,105.83 |
| Efficiency | ||||
| Inventory Turnover | 2.84 | 2.17 | 0.95 | 0.00 |
| Cash Conversion Cycle | 138.24 | 152.68 | 157.07 | 0.00 |